Kineret (anakinra), a new biotech drug for rheumatoid arthritis
July 2002
Amgen is now marketing Kineret (anakinra), a new biotech drug for rheumatoid arthritis.
It's the first interleukin-1 (IL-1) receptor antagonist.
Blocking this protein reduces joint pain and inflammation...and might slow the progression of the disease.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive